Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291237 · ClinicalTrials.gov registry record · Phase 2
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT02291237 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 172 participants.
The verdict
NCT02291237, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with symptomatic hypertrophic cardiomyopathy (HCM).
Interventions
- DRUG Placebo
- DRUG Eleclazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2015-02-05 |
| Est. Completion | 2017-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291237
The ClinicalTrials.gov registry entry for NCT02291237 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02291237 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02291237 about?
NCT02291237 is a clinical study titled "Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy". The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with symptomatic hypertrophic cardiomyopathy (HCM).
What is the current status of trial NCT02291237?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2015-02-05. Estimated completion is 2017-02-17.
What interventions are being tested in trial NCT02291237?
The interventions under investigation include: Placebo (DRUG), Eleclazine (DRUG).
Who is sponsoring clinical trial NCT02291237?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.